Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620782 | 1.00 | GSK3B (0.54) | GSK3BTAS1R3TAS1R1PDE4DMAPT | |
| SCHEMBL23112630 | 0.87 | GSK3B (0.54) | GSK3BPDE4DMAPTMEN1KMT2A | |
| SCHEMBL6136939 | 0.85 | TAS1R3 (0.53) | GSK3BTAS1R3TAS1R1PDE4DMAPT | |
| SCHEMBL12780432 | 0.85 | MEN1 (0.59) | TAS1R3TAS1R1PDE4DMAPTPOLB | |
| SCHEMBL6329414 | 0.85 | TAS1R3 (0.53) | TAS1R3TAS1R1PDE4DMAPTPOLB | |
| SCHEMBL426444 | 0.84 | TSHR (0.63) | GSK3BPDE4DMAPTPOLBMEN1 | |
| SCHEMBL29620831 | 0.84 | TSHR (0.63) | GSK3BPDE4DMAPTPOLBMEN1 | |
| SCHEMBL22570710 | 0.83 | TAS1R3 (0.51) | TAS1R3TAS1R1PDE4DMAPTPOLB | |
| SCHEMBL9155650 | 0.83 | PDE4D (0.54) | TAS1R3TAS1R1PDE4DMAPTPOLB | |
| SCHEMBL7393792 | 0.83 | POLB (0.49) | TAS1R3TAS1R1PDE4DMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232448-B1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2025-05-07 | — | — | EP | disclosed |
| EP-3956323-B1 | OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 | Halo Therapeutics Ltd (GB) | 2025-03-05 | — | — | EP | disclosed |
| US-20240158382-A1 | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor | Halo Therapeutics Ltd (GB) | 2024-05-16 | — | — | US | disclosed |
| EP-4232448-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2023-08-30 | — | — | EP | disclosed |
| US-20220274968-A1 | Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 | GBIOTECH S.À.R.L. (CH) | 2022-09-01 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
| WO-2022083853-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | GBIOTECH S.À.R.L. (CH) | 2022-04-28 | — | — | WO | disclosed |
| EP-3956323-A1 | OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 | Gbiotech S.À.R.L. (CH) | 2022-02-23 | — | — | EP | disclosed |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2021-06-03 | — | — | US | disclosed |
| US-20110183976-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | FMR LLC | 2011-07-28 | — | — | US | disclosed |
| WO-2009158473-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| EP-0835872-B1 | Benzo [b] thiophene compounds, intermediates, formulations, and methods | LILLY CO ELI (US) | 2006-03-01 | — | — | EP | disclosed |
| US-5948796-A | OSTEOPOROSIS, CANCER, CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0743938-B1 | SUBSTITUTED SPIRO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 1999-04-21 | — | — | EP | disclosed |
| EP-0639049-B1 | HALOGENATED 4'-METHOXYACETOPHENONES AS MICROBICIDES AND PRESERVATIVES | BUCKMAN LABOR INC (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0835872-A1 | Benzo [b] thiophene compounds, intermediates, formulations, and methods | ELI LILLY AND COMPANY (US) | 1998-04-15 | — | — | EP | disclosed |
| US-5466717-A | INHIBITING THE GROWTH OF MICROORGANISMS IN AN AQUEOUS SYSTEM | BUCKMAN LABORATORIES INT'L, INC. (US) | 1995-11-14 | — | — | US | disclosed |
| EP-0639049-A1 | HALOGENATED 4'-METHOXYACETOPHENONES AS MICROBICIDES AND PRESERVATIVES | BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) | 1995-02-22 | — | — | EP | disclosed |
| WO-1993022918-A1 | HALOGENATED 4'-METHOXYACETOPHENONES AS MICROBICIDES AND PRESERVATIVES | BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158382-A1 | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor | FFAR1, FFAR2, FFAR3 | GSK3B 4031/4885TAS1R3 768/4885TAS1R1 685/4885 |
| US-11345694-B2 | Antibacterial compounds | CFTR, MRPL21, NQO1 | GSK3B 1521/4885TAS1R3 3401/4885TAS1R1 3198/4885 |
| US-20110183976-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | ACHE, PDE7A, PDE5A | GSK3B 934/4885TAS1R3 4361/4885TAS1R1 4194/4885 |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | CFTR, MRPL21, NQO1 | GSK3B 1521/4885TAS1R3 3401/4885TAS1R1 3198/4885 |
| US-20220274968-A1 | Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 | FFAR2, FFAR1, FFAR3 | GSK3B 1838/4885TAS1R3 275/4885TAS1R1 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.